Drug Enforcement Administration

The Drug Enforcement Administration (DEA) is presented less as a single actor in one investigation than as part of a long-running contest over how drug use should be controlled: through restriction and enforcement, or through treatment. The book traces one strand of that history to the agency’s predecessor, then turns to the DEA’s place in debates over prescription painkillers and its warnings about increasingly potent illicit opioids. Across those settings, drug policy appears not as a settled line between dangerous and therapeutic substances, but as a shifting boundary with consequences for patients, clinicians, and first responders.

Institutional Predecessor and Treatment

The book identifies the Federal Bureau of Narcotics as the DEA’s precursor and uses the earlier agency to establish the historical tension around medication-assisted treatment. After American researchers found that Methadone could relieve opioid withdrawal, the Federal Bureau of Narcotics opposed its use in addiction treatment. It characterized the drug as unsafe after studies found that people dependent on morphine liked it, treating the possibility of pleasurable effects as a reason for suspicion. In the 1960s, it also harassed some of the doctors who used Methadone to treat morphine and heroin addiction.

This history is not a claim that the later DEA made those specific decisions. Rather, the institutional connection gives the book a way to show how drug-control thinking could treat a medication’s capacity to relieve suffering and its capacity to produce pleasure as evidence in conflict. During the following decade, researchers developed compounds intended to block opioid euphoria and dangerous respiratory depression. The account places those developments against the earlier resistance to treating addiction with drugs, illustrating a persistent policy dispute over whether medication is a remedy, a risk, or both.

Prescription Drugs and Contested Controls

The DEA enters the book’s discussion of prescription controls through a 2014 rule targeting popular painkillers. The surrounding account describes regulations that limited doctors and the controversial rescheduling of hydrocodone combination products. That placement matters: a restriction intended to control access to a widely used opioid also affected the conditions under which clinicians could prescribe pain medication. The book presents rescheduling as contested policy, not as an uncomplicated solution to misuse.

The account also distinguishes drug control from the decisions that shaped OxyContin’s approval and promotion. The evidence about that drug’s 1995 application and the risks of crushing and injecting tablets concerns FDA review, while the DEA appears in the later debate over restrictions and diversion. Keeping those responsibilities distinct clarifies the book’s broader institutional picture: the opioid crisis developed across multiple systems, and enforcement rules were only one part of a chain that also included approval, marketing, prescribing, and access to treatment.

Illicit Fentanyl and the Limits of Bans

As the crisis shifted toward illicit synthetic opioids, the DEA’s public warnings focused on the speed with which drug producers could respond to restrictions. The book cites DEA spokesman Russ Baer in connection with accounts of bans on fentanyl derivatives and the emergence of new, potent opioids from underground laboratories. The pattern described is one of rapid substitution: banning one derivative did not necessarily remove the supply, because producers could devise other compounds faster than authorities could respond. The resulting enforcement problem was not simply identifying and prohibiting a substance; it was keeping pace with a changing supply.

That challenge is set against the scale of the danger to people encountering the drugs outside controlled settings. The book describes the DEA’s June 2017 recommendation that first responders use safety goggles, masks, and even hazmat suits to guard against contact with fentanyl and other powerful synthetics. The recommendation followed reports of officers receiving naloxone after inadvertently touching such substances during calls. The warning extended the crisis beyond users and their families to the people arriving to assist them, while underscoring the uncertainty faced by responders dealing with a rapidly changing drug supply.

Enforcement in a Public-Health Crisis

The DEA’s role in the book is therefore defined by a tension between the need to restrict dangerous drugs and the limits of restriction as a response to addiction. Its predecessor’s resistance to Methadone treatment supplies the historical example; the modern discussion of hydrocodone rescheduling and fentanyl derivatives shows how controls continued to shape access and enforcement. These episodes do not establish that every restriction failed, nor do they make the agency responsible for decisions made elsewhere. They show instead that enforcement operates within a wider system where the drugs, the rules, and the available responses change over time.

That wider system is especially visible in the contrast between controlling supply and arranging care. The book describes severe shortages of medication-assisted treatment providers and detoxification beds, and recounts local efforts to connect overdose patients to treatment. Those service gaps are not presented as DEA programs or decisions. Their relevance is structural: when bans and prescribing limits are discussed alongside a shortage of treatment, the account makes clear that controlling drugs and ensuring care are different tasks. The agency’s appearance across the book thus marks the enforcement side of a crisis whose consequences cannot be addressed by enforcement alone.